Parameter
|
Training (n = 132)
|
Validation (n = 120)
|
P value
|
---|
Sex
| | |
.614
|
No. of men
|
72 (54.5)
|
61 (50.8)
| |
No. of women
|
60 (45.5)
|
59 (49.2)
| |
Age
| | |
.703
|
< 60 (years)
|
76 (57.6)
|
72 (60.0)
| |
≥ 60 (years)
|
56 (42.4)
|
48 (40.0)
| |
BMI
|
23.86 ± 3.06
|
23.67 ± 2.88
|
.618
|
Laboratory findingsa
| | | |
WBC (109/L)
|
5.45 ± 2.15
|
5.20 ± 2.04
|
.354
|
FBG (mmol/L)
|
8.6 ± 4.2
|
9.3 ± 5.4
|
.250
|
FINS (mIU/L)
|
14.86 ± 10.37
|
16.33 ± 11.49
|
.287
|
AST (IU/mL)
|
57.59 ± 68.80
|
69.88 ± 121.65
|
.319
|
ALT (IU/mL)
|
86.45 ± 145.88
|
87.22 ± 169.00
|
.969
|
GGT (IU/mL)
|
92.16 ± 118.81
|
77.40 ± 106.36
|
.302
|
ALP (IU/mL)
|
98.39 ± 60.50
|
87.78 ± 67.94
|
.191
|
Platelet count (109/L)
|
151.96 ± 59.70
|
148.97 ± 68.49
|
.711
|
Cholesterol (mmol/L)
|
3.96 ± 1.00
|
4.04 ± 0.92
|
.527
|
TG (mmol/L)
|
1.80 ± 1.21
|
1.60 ± 1.05
|
.106
|
INR
|
1.17 ± 0.18
|
1.17 ± 0.15
|
.774
|
APRI
|
1.17 ± 1.58
|
1.52 ± 3.31
|
.275
|
FIB-4
|
2.16 ± 1.67
|
2.69 ± 3.42
|
.117
|
Histologic activity grade
| | |
.271
|
A0
|
27 (20.5)
|
23 (19.2)
|
.875
|
A1
|
49 (37.1)
|
57 (47.5)
|
.099
|
A2
|
40 (30.3)
|
32 (26.7)
|
.577
|
A3
|
16 (12.1)
|
8 (6.7)
|
.197
|
Histologic fibrosis stage
| | |
.787
|
F0
|
11 (8.3)
|
10 (8.3)
|
> .99
|
F1
|
16 (12.1)
|
21 (17.5)
|
.285
|
F2
|
25 (18.9)
|
21 (17.5)
|
.871
|
F3
|
29 (22.0)
|
22 (18.3)
|
.531
|
F4
|
51 (38.6)
|
46 (38.3)
|
.961
|
TE (kPa)
|
11.13 ± 5.21
|
11.05 ± 5.87
|
.914
|
CK18 (ng/L)
|
105.41 ± 28.33
|
103.24 ± 26.67
|
.533
|
- Except where indicated, data are numbers of patients, with percentages in parentheses
- ALT, alanine transferase; ALP, alkaline phosphatase; APRI, aspartate transaminase-to-platelet ratio; AST, aspartate transaminase; BMI, body mass index; CK18, cytokeratin 18; FBG, fasting blood glucose; FINS, fasting insulin; FIB-4, fibrosis-4 index; GGT, γ-glutamyl transferase; INR, international normalized ratio; TE, transient elastography; TG, triglyceride; WBC, white blood cell
- aData are presented as means ± standard deviations